A 54-year-old man with a 7-year history of early-onset, slowly progressive dementia and motor impairment characterised by diffuse, non-enhancing white matter signal change. Neuropathologic examination demonstrated subcortical pigmentation with neuroaxonal spheroid formation, profound axonal loss with secondary myelin degeneration and widespread βA4 immunopositivity involving meningeal and subcortical vessels. There was relative sparing of brain stem and cerebellar white matter. The neocortex was normal. The appearances expand the spectrum of adult-onset neuroaxonal leucoencephalopathy with spheroids (NALS) and demonstrate that vascular βA4 amyloid plays a key role in the white matter pathology of NALS.

Keywords:
Amyloid, Dementia, Leucoencephalopathy, late-onset, Neuroaxonal spheroids
1.
Merino JG, Hachinski V: Leukoaraiosis: Reifying rarefaction. Arch Neurol 2000;57:925–926.
2.
Kalimo H, Ruchoux MM, Viitanen M, Kalaria RN: CADASIL: A common form of hereditary arteriopathy causing brain infarcts and dementia. Brain Pathol 2002;12:371–384.
3.
Cengiz N, Ozbenli T, Onar M, Yildiz L, Ertas B: Adult metachromatic leukodystrophy: Three cases with normal nerve conduction velocities in a family. Acta Neurol Scand 2002;105:454–457.
4.
Teive HA, Brandi IV, Camargo CH, Bittencourt MA, Bonfim CM, Friedrich ML, de Medeiros CR, Werneck LC, Pasquini R: Reversible posterior leucoencephalopathy syndrome associated with bone marrow transplantation. Arq Neuropsiquiatr 2001;59:784–789.
5.
Pfefferbaum A, Rosenbloom M, Serventi KL, Sullivan EV: Corpus callosum, pons, and cortical white matter in alcoholic women. Alcohol Clin Exp Res 2002;26:400–406.
6.
Cairncross JG, Pexman W, Farrell M: Complications of chemotherapy. Can J Neurol Sci 1985;12:149–153.
7.
Axelsson R, Roytta M, Sourander P, Akesson HO, Andersen O: Hereditary diffuse leucoencephalopathy with spheroids. Acta Psychiatr Scand Suppl 1984;314:1–65.
8.
Goodman LA, Dickson DW: Nonhereditary diffuse leukoencephalopathy with spheroids presenting as early-onset rapidly progressive dementia. J Neuropathol Exp Neurol 1995;54:471.
9.
van der Knaap MS, Naidu S, Kleinschmidt-Demasters BK, Kamphorst W, Weinstein HC: Autosomal dominant diffuse leukoencephalopathy with neuroaxonal spheroids. Neurology 2000;54:463–468.
10.
Minagawa M, Maeshiro H, Kato K, Shioda K: A rare case of leukodystrophy – neuroaxonal leukodystrophy (Seitelberger). Seishin Shinkeigaku Zasshi 1980;82:488–503 [in Japanese].
11.
Yamashita M, Yamamoto T: Neuroaxonal leukoencephalopathy with axonal spheroids Eur Neurol 2002;48:20–25.
12.
Cervos-Navarro J, Urich H: Metabolic and Degenerative Diseases of the Central Nervous System. London, Academic Press, 1995, pp 497–519.
13.
Seitelberger F: Neuropathological conditions related to neuroaxonal dystrophy. Acta Neuropathol (Berl) 1971;5(suppl 5):17–29.
14.
Matsuyama H, Watanabe I, Mihm MC, Richardson EP Jr: Dermatoleukodystrophy with neuroaxonal spheroids. Arch Neurol 1978;35:329–336.
15.
Machinami R: Membranous lipodystrophy of the bone. Ann Pathol 2001;21:524–528.
16.
Shapiro EG, Lockman LA, Knopman D, Krivit W: Characteristics of the dementia in late-onset metachromatic leukodystrophy. Neurology 1994;44:662–665.
17.
Moser HW, Loes DJ, Melhem ER, Raymond GV, Bezman L, Cox CS, Lu SE: X-linked adrenoleukodystrophy: Overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics 2000;31:227–239.
18.
Shannon P, Wherrett JR, Nag S: A rare form of adult onset leukodystrophy: Orthochromatic leukodystrophy with pigmented glia. Can J Neurol Sci 1997;24:146–150.
19.
Constantinidis J, Wisniewski TM: The dominant form of the pigmentary orthochromatic leukodystrophy. Acta Neuropathol (Berl) 1991;82:483–487.
20.
Knopman D, Sung JH, Davis D: Progressive familial leukodystrophy of late onset. Neurology 1996;46:429–434.
21.
Quattrocolo G, Leombruni S, Vaula G, Bergui M, Riva A, Bradac GB, Bergamini L: Autosomal dominant late-onset leukoencephalopathy. Clinical report of a new Italian family. Eur Neurol 1997;37:53–61.
22.
Eldridge R, Anayiotos CP, Schlesinger S, Cowen D, Bever C, Patronas N, McFarland H: Hereditary adult-onset leukodystrophy simulating chronic progressive multiple sclerosis. N Engl J Med 1984;311:948–953.
23.
Abe K, Ikeda M, Watase K, Tanabe H, Fujimura H, Yorifuji S, Ueno S, Mezaki T, Mori T: A kindred of hereditary adult-onset leukodystrophy with sparing of the optic radiations. Neuroradiology 1993;35:281–283.
24.
Bergui M, Bradac GB, Leombruni S, Vaula G, Quattrocolo G: MRI and CT in an autosomal-dominant, adult-onset leukodystrophy. Neuroradiology 1997;39:423–426.
25.
Sveinbjornsdottir S, Blondal H, Gudmundsson G, Kjartansson O, Jonsdottir S, Gudmundsson G: Progressive dementia and leucoencephalopathy as the initial presentation of late onset hereditary cystatin-C amyloidosis. Clinicopathological presentation of two cases. J Neurol Sci 1996;140:101–108.
26.
Sarazin M, Amarenco P, Mikol J, Dimitri D, Lot G, Bousser MG: Reversible leukoencephalopathy in cerebral amyloid angiopathy presenting as subacute dementia. Eur J Neurol 2002;9:353–358.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.